St. Louis, Missouri
Kereos, Inc. develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease earlier and more specifically than currently possible. The specificity and unique capabilities of Kereos’ molecular imaging agents enable earlier and more definitive diagnosis of disease. Similarly, Kereos’ targeted therapeutics seek out definitive disease biomarkers and carry powerful payloads of proven chemotherapeutics, making them potentially more effective and less toxic in treating disease. With its lead candidates projected to enter the clinic in 2008, Kereos is at the forefront in bringing targeted therapy and molecular imaging to patients. Independently and with its partners, Kereos is committed to developing its pipeline of products tackling America’s top two killers.